PDF(Pubmed)
Abstract：
Bronchiectasis is a heterogeneous disease with multiple aetiologies and diverse clinical features. There is a general consensus that optimal treatment requires precision medicine approaches focused on specific treatable disease characteristics, known as treatable traits. Identifying subtypes of conditions with distinct underlying biology (endotypes) depends on the identification of biomarkers that are associated with disease features, prognosis or treatment response and which can be applied in clinical practice. Bronchiectasis is a disease characterised by inflammation, infection, structural lung damage and impaired mucociliary clearance. Increasingly there are available methods to measure each of these components of the disease, revealing heterogeneous inflammatory profiles, microbiota, radiology and mucus and epithelial biology in patients with bronchiectasis. Using emerging biomarkers and omics technologies to guide treatment in bronchiectasis is a promising field of research. Here we review the most recent data on biomarkers in bronchiectasis.
摘要：
支气管扩张是一种异质性疾病，具有多种病因和多种临床特征。人们普遍认为，最佳治疗需要专注于特定可治疗疾病特征的精准医学方法。被称为可治疗的特征。识别具有不同潜在生物学（内生型）的疾病亚型取决于与疾病特征相关的生物标志物的识别。预后或治疗反应，可应用于临床实践。支气管扩张是一种以炎症为特征的疾病，感染,结构性肺损伤和粘液纤毛清除受损。越来越多的可用的方法来测量疾病的这些组成部分，揭示了异质性的炎症特征，微生物群,支气管扩张患者的放射学和粘液和上皮生物学。使用新兴的生物标志物和组学技术来指导支气管扩张症的治疗是一个有前途的研究领域。在这里，我们回顾了有关支气管扩张中生物标志物的最新数据。
